Evidence map›Paper›PMID 33151471›Full record

SynthesisTargeted oncology2020

Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis.

Jacques Raphael, Cory Lefebvre, Alison Allan, Joelle Helou, Gabriel Boldt, Theodore Vandenberg, Phillip S Blanchette

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Targeted oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jacques RaphaelDivision of Medical Oncology, Department of Oncology, Western University, London Regional Cancer Program, 800 Commissioners road east, London, ON, N6A 5W9, Canada. jacques.raphael@lhsc.on.ca.
Cory LefebvreDepartment of Anatomy and Cell Biology, Western University, London, ON, Canada.
Alison AllanDepartment of Anatomy and Cell Biology, Western University, London, ON, Canada.
Joelle HelouDepartment of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
Gabriel BoldtDivision of Medical Oncology, Department of Oncology, Western University, London Regional Cancer Program, 800 Commissioners road east, London, ON, N6A 5W9, Canada.
Theodore VandenbergDivision of Medical Oncology, Department of Oncology, Western University, London Regional Cancer Program, 800 Commissioners road east, London, ON, N6A 5W9, Canada.
Phillip S BlanchetteDivision of Medical Oncology, Department of Oncology, Western University, London Regional Cancer Program, 800 Commissioners road east, London, ON, N6A 5W9, Canada.
Western University · CAPrincess Margaret Cancer Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEverolimus plus exemestane is approved for the treatment of hormone receptor-positive metastatic breast cancer (MBC) after progression on nonsteroidal aromatase inhibitors. The role of everolimus is less well defined in other breast cancer phenotypes and in combination with other drugs.

objectivesWe conducted a systematic review and meta-analysis to assess the efficacy and safety of adding everolimus to standard of care (SoC) in MBC regardless of tumor phenotype and treatment type.

methodsThe electronic databases PubMed and EMBASE were searched for eligible randomized trials. Pooled hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) and pooled risk ratios (RR) and odds ratios for objective response rates, disease control rate (DCR), and grade 3 or higher toxicity were meta-analyzed. Subgroup analyses compared survival outcomes by tumor phenotype.

resultsData from 2826 patients from eight trials were analyzed. The addition of everolimus to SoC reduced the risk of disease progression by 29% (HR 0.71; 95% confidence interval [CI] 0.56-0.90). This did not translate into an OS benefit (HR 0.95; 95% CI 0.80-1.13). In addition, everolimus improved the DCR (RR 0.82; 95% CI 0.68-0.98), whereas it increased the risk of developing grade 3 or higher toxicity. The PFS benefit was more prominent for patients with hormone receptor-positive (+)/human epidermal growth factor receptor 2 (HER2)-negative (-) disease. For the HER2 (+) subgroup, the PFS benefit was restricted to patients with hormone receptor (-) disease.

conclusionsEverolimus reduces the risk of disease progression in hormone receptor (+) MBC. In patients with HER2 (+) disease, the benefit is limited for those with hormone receptor (-) disease. Given the approval and use of newer drugs in MBC, clinical trials and real-world data are needed to confirm the benefit of everolimus and define the best treatment sequence strategy to adopt in that setting.

Indexed as

Antineoplastic AgentsBreast NeoplasmsEverolimusFemaleHumansAntineoplastic AgentsEverolimus

Identifiers

PMID33151471
OpenAlexW3095962378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.